The National Cancer Institute approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I – 10410
A Phase 1 Study of IPdR in Combination with Capecitabine and Radiotherapy in Rectal Cancer
University Health Network Princess Margaret Cancer Center LAO
Kinsella, Timothy James
(401) 444-6203
Phase II – 10398
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma
National Cancer Institute LAO
Chen, A P
(240) 781-3320
Phase II – S2000
A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab Vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases
SWOG
Eroglu, Zeynep
(813) 745-8581
Phase II/III – EA2197
Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial
ECOG-ACRIN Cancer Research Group
Maithel, Shishir Kumar
(404) 617-7936
Phase III – EA2176
A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-NaÔve Metastatic Anal Cancer Patients
ECOG-ACRIN Cancer Research Group
Eng, Cathy
615-936-0809
Phase III – EA5182
Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
ECOG-ACRIN Cancer Research Group
Yu, Helena A.
(646) 888-4274
Phase III – NRG-HN007
An Open-Label, Phase III Study of Platinum-Gemcitabine with or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
NRG Oncology
Ma, Brigette Buig-Yue
852- 35052118
Phase Other – 10323
Cancer Moonshot Biobank Research Protocol
Division of Cancer Treatment and Diagnosis
Moore, Helen M.
(240) 276-5713
